(−)1‐(Benzofuran‐2‐yl)‐2‐propylaminopentane, [(−)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain

@article{Knoll19991Benzofuran2yl2propylaminopentaneA,
  title={(−)1‐(Benzofuran‐2‐yl)‐2‐propylaminopentane, [(−)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain},
  author={Joseph Knoll and Fumio. Yoneda and Bertha Knoll and Hironori Ohde and Ildikó Miklya},
  journal={British Journal of Pharmacology},
  year={1999},
  volume={128}
}
The brain constituents β‐phenylethylamine (PEA) and tryptamine enhance the impulse propagation mediated transmitter release (exocytosis) from the catecholaminergic and serotoninergic neurons in the brain (‘catecholaminergic/serotoninergic activity enhancer, CAE/SAE, effect’). (−)Deprenyl (Selegiline) and (−)1‐phenyl‐2‐propylaminopentane [(−)PPAP] are amphetamine derived CAE substances devoid of the catecholamine releasing property. By changing the aromatic ring in PPAP we developed highly… 

References

SHOWING 1-10 OF 41 REFERENCES

(-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain.

  • J. Knoll
  • Biology, Psychology
    Pharmacology & toxicology
  • 1998
It may be supposed that a prophylactic low dose administration of a safe catecholaminergic activity enhancer substance during the postdevelopmental phase of life will slow the age-related decline of behavioral performances, delay natural death and decrease susceptibility to Parkinson's disease and Alzheimer's disease.

Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition.

  • J. KnollI. Miklya
  • Biology, Chemistry
    Archives internationales de pharmacodynamie et de therapie
  • 1994
The results prove that the described effects of deprenyl are unrelated to MAO-B inhibition and indicate the existence of hitherto unknown catecholaminergic and serotoninergic activity enhancer mechanisms in the brain, of which the former is stimulated and the latter inhibited by multiple, small dose administrations ofdeprenyl and related substances.

The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.

Early deprenyl therapy delays the requirement for antiparkinsonian medication, possibly by slowing progression of the disease.

Rescue of dying neurons: A new action for deprenyl in MPTP parkinsonism

Research shows that deprenyl can increase SNc neuronal survival by a mechanism that is independent of the blockade of MPTP's conversion to MPP+ and may be responsible for slowing the progressioon of PD.

Is there a "non-MAO" macromolecular target for L-deprenyl?: Studies on MAOB mutant mice.

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

In patients with moderately severe impairment from Alzheimer's disease, treatment with selegiline or alpha-tocopherol slows the progression of disease.

L-deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression.